Examining the Role of Vitamin D in Colorectal Cancer Survival

Oncology & Biotech NewsJanuary 2014
Volume 8
Issue 1

In Partnership With:

Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer.

Kimmie Ng, MD, MPH

Assistant Professor of Medicine

Center for Gastrointestinal Oncology

Dana-Farber Cancer Institute

Harvard Medical Center

Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer. Little is known, however, about how these factors may impact the survival of patients with established colorectal cancer, many of whom seek to understand which diet and lifestyle behaviors—beyond standard treatment with surgery, chemotherapy, or radiation—will improve their outcome.

Following on the recommendation of an American Cancer Society consensus panel highlighting the urgent need for more research on the effect of nutrition and physical activity on the prognosis of cancer survivors, the Center for Gastrointestinal Oncology at Dana-Farber Cancer Institute has developed an innovative, crossdisciplinary, translational research program to elucidate the role of diet and lifestyle behaviors in the survival of colorectal cancer patients.

Among the factors that we have identified as being potentially protective are exercise,1-3 avoiding a Western pattern diet,4 maintaining a normal body-mass index,5 aspirin use,6,7 and vitamin D status. For vitamin D, in particular, abundant data from the laboratory as well as epidemiologic studies support a potential antineoplastic effect. Efforts are underway to further understand the biologic mechanisms by which vitamin D may contribute to colorectal cancer pathogenesis and the potential clinical impact of supplementation on patient management.

The hypothesis that vitamin D status is related to colorectal cancer has received strong experimental support over the past two decades, based on the almost ubiquitous expression in colon cancer cells of the vitamin D receptor (VDR)8,9 and 1-a-hydroxylase (CYP27B1),10 which converts plasma 25-hydroxyvitamin D3 [25(OH)D] into 1,25-dihyroxycholecalciferol [1,25(OH)2D], the active metabolite. Binding of VDR by 1,25(OH)2D leads to transcriptional control of target genes, resulting in induction of differentiation and apoptosis,11,12 and inhibition of proliferation,13 angiogenesis,14,15 and metastatic potential.16,17

Vitamin D inhibits growth and promotes differentiation of colorectal cancer cell lines and xenografts.14,18-21 Rats maintained on a diet enriched in 1,25(OH)2D develop fewer intestinal tumors and metastases compared to control animals.17,22 Treatment of ApcMin mice with vitamin D or a synthetic analog reduces the size of intestinal adenomas,23-25 and epidemiologic data also suggest that vitamin D plays a role in colorectal cancer carcinogenesis. A meta-analysis of nine prospective studies showed that individuals with higher plasma levels of 25(OH)D, the best indicator of vitamin D status, have a significantly reduced risk of developing colorectal cancer.26

The influence of vitamin D on survival of patients with established colorectal cancer remains uncertain, however, and we conducted several studies to try and address this knowledge gap.

Figure. Plasma 25(OH)D and Survival in 304 Colorectal Cancer Patients (NHS/HPFS)

Adjusted for age, gender, stage, grade, site, year of diagnosis, season of blood draw, BMI, and post-diagnosis physical activity. (Ng K, et al. J Clin Oncol. 2008;26[18]:2984-2991.)

Among 304 colorectal cancer patients in the Nurses’ Health Study (NHS) and the Health Professionals Follow- Up Study (HPFS) who had blood samples available, we measured 25(OH)D concentrations prior to colorectal cancer diagnosis and assessed for a correlation with survival. We found that higher plasma 25(OH)D levels were associated with a significant reduction in overall mortality (Figure).27 This finding was subsequently confirmed in another study of 1017 colorectal cancer patients in the NHS and HPFS, where higher postdiagnosis vitamin D scores calculated from known clinical determinants of vitamin D status were found to be significantly associated with improved cancer-specific (adjusted hazard ratio [HR] = 0.50; 95% CI, 0.26-0.95; P trend = .02) and overall survival (HR = 0.62; 95% CI, 0.42- 0.93; P trend = .002).28 In subgroup analyses, the benefit of higher plasma 25(OH)D seemed greater in stage III and IV patients than stage I and II (adjusted HR = 0.40 vs 0.90, respectively, comparing extreme quartiles).27

To further test the benefit of vitamin D in advancedstage colorectal cancer, we conducted an analysis of plasma 25(OH)D levels drawn at study registration in 515 stage IV colorectal cancer patients enrolled in a completed, National Cancer Institute-sponsored clinical trial of palliative chemotherapy (North Central Cancer Treatment Group N9741).29 We found extremely low circulating concentrations of 25(OH)D in this population, with a median level of 20.0 ng/ mL. Indeed, only 10% of the cohort had levels ≥33 ng/mL, the threshold believed to be required for a protective effect of vitamin D on colorectal cancer risk.30 These low levels of plasma 25(OH)D are especially concerning in light of laboratory and epidemiologic evidence that higher levels are associated with improved outcome.

Given the prevalence of vitamin D deficiency and insufficiency among metastatic colorectal cancer patients, the hypothesis-generating finding of a greater benefit of vitamin D among advanced-stage patients, and preclinical studies revealing potential synergy between vitamin and cytotoxic drugs such as platinums31-34 and 5-FU,35 we are now translating our observational findings into a clinical intervention for patients.

We are currently conducting a multicenter, randomized, blinded, placebo-controlled phase II study of FOLFOX + bevacizumab in combination with either standard-dose vitamin D3 at 400 IU/day versus higher- dose vitamin D3 at 4000 IU/day in previously untreated, stage IV colorectal cancer patients, with a primary endpoint of progression-free survival (ClinicalTrials.gov identifier NCT01516216). Approximately 120 patients will be enrolled on the study, and accrual is actively ongoing at multiple centers across the United States. Serial plasma and DNA samples and archival tumor tissue will be collected from all patients and banked for future correlative studies.

These correlative studies will be critical to fully understanding the role of vitamin D in colorectal cancer pathogenesis. Despite the abundant laboratory and observational data discussed above, the exact molecular and genetic mechanisms underlying vitamin D’s antineoplastic effects are unknown. Consequently, an entire project in our Dana-Farber/Harvard Cancer Center SPORE (Specialized Programs of Research Excellence) in gastrointestinal cancer is devoted to investigating the transcriptional targets of VDR in cell lines, xenograft mouse models, and human primary colon tumor samples. Moreover, multiple analyses of germline polymorphisms in vitamin D pathway genes are ongoing to determine if genetic variation significantly affects response to vitamin D supplementation as well as colorectal cancer patient outcome.

The potential to modulate the progression of colorectal cancer through nutritional and lifestyle factors is very real but insufficiently studied, and a clinical and translational approach that steps beyond purely observational studies is required to establish causality. In addition, elucidation of a biological mechanism underlying these clinical findings would enhance the acceptability of vitamin D as critical for cancer prevention and treatment.

In this era of expensive and often toxic antineoplastic drugs, vitamin D represents an attractive treatment option for patients and oncologists with respect to both safety and cost, and improving understanding of vitamin D in colorectal cancer could potentially shift the paradigm in managing this disease.


  1. Meyerhardt JA, Giovannucci EL, Ogino S, et al. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009;169:2102-2108.
  2. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24:3535-3541.
  3. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24:3527-3534.
  4. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298:754-764.
  5. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484-495.
  6. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-658.
  7. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562-572.
  8. Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res. 1991;51:1227-1233.
  9. Vandewalle B, Adenis A, Hornez L, Revillion F, Lefebvre J. 1,25-dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. Cancer Lett. 1994;86:67-73.
  10. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888-894.
  11. Vandewalle B, Wattez N, Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett. 1995;97:99-106.
  12. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000;60:2304-2312.
  13. Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C, Brasitus TA. A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology. 2000;141:3931-3939.
  14. Iseki K, Tatsuta M, Uehara H, et al. Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer. 1999;81:730-733.
  15. Fernandez-Garcia NI, Palmer HG, Garcia M, et al. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene. 2005;24:6533-6544.
  16. Lamprecht SA, Lipkin M. Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci. 2001;952:73-87.
  17. Evans SR, Shchepotin EI, Young H, Rochon J, Uskokovic M, Shchepotin IB. 1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol. 2000;16:1249-1254.
  18. Shabahang M, Buras RR, Davoodi F, et al. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res. 1994;54:4057-4064.
  19. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987;47:21-25.
  20. Giuliano AR, Franceschi RT, Wood RJ. Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. Arch Biochem Biophys. 1991;285:261-269.
  21. Zhao X, Feldman D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology. 1993;132:1808-1814.
  22. Beaty MM, Lee EY, Glauert HP. Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets. J Nutr. 1993;123:144-152.
  23. Huerta S, Irwin RW, Heber D, et al. 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res. 2002;62:741-746.
  24. Zheng W, Wong KE, Zhang Z, et al. Inactivation of the vitamin D receptor in APC(min/+) mice reveals a critical role for the vitamin D receptor in intestinal tumor growth. Int J Cancer. 2011;doi:10.1002/ijc.25992.
  25. Larriba MJ, Ordonez-Moran P, Chicote I, et al. Vitamin D Receptor Deficiency Enhances Wnt/beta-Catenin Signaling and Tumor Burden in Colon Cancer. PLoS One. 2011;6:e23524.
  26. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. 2011;29:3775-3782.
  27. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26:2984-2991.
  28. Ng K, Wolpin BM, Meyerhardt JA, et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer. 2009;101:916-923.
  29. Ng K, Sargent DJ, Goldberg RM, et al. Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. J Clin Oncol. 2011;29:1599-1606.
  30. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. 2007;32:210-216.
  31. Cho YL, Christensen C, Saunders DE, et al. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 1991;51:2848-2853.
  32. Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999;5:695-703.
  33. Kulkarni AD, van Ginkel PR, Darjatmoko SR, Lindstrom MJ, Albert DM. Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. Br J Ophthalmol. 2009;93:1105-1108.
  34. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 1997;57:3759-3764.
  35. Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer .2010;126:631-639.

Related Videos
Pasi A. Jänne, MD, PhD
Alessandro Di Federico, MD
In this fourth episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss what is known about the utilization of endoscopic radiofrequency ablation in nonmetastatic pancreatic adenocarcinoma and the potential for this approach in the paradigm.
Jia Luo, MD
Experts on GVHD
Experts on GVHD
Marwan G. Fakih, MD
Paul G. Richardson, MD
In this third episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, share how they would best utilize genetic testing results obtained from endoscopic ultrasound–guided biopsies in pancreatic ductal adenocarcinomas.
Experts on GVHD
Related Content